Clinical Study to Investigate the Safety and Efficacy of MLC601 in 150 Iranian Patients After Stroke
NCT ID: NCT01336153
Last Updated: 2011-05-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
150 participants
INTERVENTIONAL
2009-08-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intracerebral Transplantation of Neural Stem Cells for the Treatment of Ischemic Stroke
NCT03296618
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
NCT04415164
Establishment and Evaluation to the Effects of a Clinical Pathway for Acute Ischemic Stroke
NCT00966316
Lu's Acupuncture and Moxibustion Treatment on Stroke
NCT01806233
NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects
NCT01847924
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MLC601
MLC601 (NeuroAideTM) is a TCM which is used extensively in China to improve recovery after stroke. It combines several herbal and animal components.
MLC601
group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month
Placebo
Placebo
group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MLC601
group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month
Placebo
group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* \< one month after stroke,
* ischemic cerebral stroke,
* signed informed consent form.
Exclusion Criteria
* ischemic stroke combined with hemorrhage, severe renal or liver failure, dementia, psychosis and history of seizure disorder, history of previous stroke, and hemoglobin level less than 10mg/dl on admission.
30 Years
72 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shahid Beheshti University of Medical Sciences
OTHER
Shahid Beheshti University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ministry of Health
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RN89-01-117-7548
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.